Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Postoperative radiation and hormonal therapy for men with node-positive prostate cancer: a new standard?

Rose BS.

BJU Int. 2019 Feb;123(2):199-200. doi: 10.1111/bju.14501. No abstract available.

PMID:
30656836
2.

The use of combined radiation therapy and hormonal therapy in the management of lymph node-positive prostate cancer.

Whittington R, Malkowicz SB, Machtay M, Van Arsdalen K, Barnes MM, Broderick GA, Wein AJ.

Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):673-80.

PMID:
9336149
3.

Combined hormonal and radiation therapy for lymph node-positive prostate cancer.

Whittington R, Malkowicz B, Barnes MM, Broderick GA, Van Arsdalen K, Dougherty MJ, Wein AJ.

Urology. 1995 Aug;46(2):213-9.

PMID:
7542824
4.

Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer.

Robnett TJ, Whittington R, Malkowicz SB, Brereton HD, Van Arsdalen K, Drach G, Wein AJ.

Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1146-51.

PMID:
12128114
5.

Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.

Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML.

J Urol. 2007 Sep;178(3 Pt 1):864-70; discussion 870-1. Epub 2007 Jul 16.

PMID:
17631342
6.

Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials.

Roach M 3rd, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Grignon D.

J Urol. 2003 Jan;169(1):245-50.

PMID:
12478146
7.

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.

Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D.

N Engl J Med. 1999 Dec 9;341(24):1781-8.

9.
10.

Radiation therapy combined with hormone therapy for prostate cancer.

Lee AK.

Semin Radiat Oncol. 2006 Jan;16(1):20-8. Review.

PMID:
16378903
11.

Use of hormonal therapy in men with metastatic prostate cancer.

Lu-Yao G, Moore DF, Oleynick J, Dipaola RS, Yao SL.

J Urol. 2006 Aug;176(2):526-31.

PMID:
16813882
12.

Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis.

Briganti A, Karnes RJ, Da Pozzo LF, Cozzarini C, Capitanio U, Gallina A, Suardi N, Bianchi M, Tutolo M, Salonia A, Di Muzio N, Rigatti P, Montorsi F, Blute M.

Eur Urol. 2011 May;59(5):832-40. doi: 10.1016/j.eururo.2011.02.024. Epub 2011 Feb 22.

PMID:
21354694
14.

The PROCAINA (PROstate CAncer INdication Attitudes) Project (Part I): a survey among Italian radiation oncologists on postoperative radiotherapy in prostate cancer.

Alongi F, De Bari B, Franco P, Ciammella P, Chekrine T, Livi L, Jereczek-Fossa BA, Filippi AR; AIRO Young and AIRO Prostate cancer Working Group.

Radiol Med. 2013 Jun;118(4):660-78. doi: 10.1007/s11547-012-0913-8. Epub 2013 Jan 28.

PMID:
23358818
15.

Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.

Zincke H, Lau W, Bergstralh E, Blute ML.

J Urol. 2001 Dec;166(6):2208-15.

PMID:
11696737
16.

The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.

Bianchi L, Nini A, Bianchi M, Gandaglia G, Fossati N, Suardi N, Moschini M, Dell'Oglio P, Schiavina R, Montorsi F, Briganti A.

Eur Urol. 2016 Jun;69(6):1142-8. doi: 10.1016/j.eururo.2015.12.010. Epub 2015 Dec 31.

PMID:
26749093
17.

The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer.

Masterson TA, Bianco FJ Jr, Vickers AJ, DiBlasio CJ, Fearn PA, Rabbani F, Eastham JA, Scardino PT.

J Urol. 2006 Apr;175(4):1320-4; discussion 1324-5.

18.

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE investigators.

Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5. Epub 2015 Dec 21.

19.

Patterns of local failure following prostate brachytherapy.

Stone NN, Stock RG, White I, Unger P.

J Urol. 2007 May;177(5):1759-63; duscussion 1763-4.

PMID:
17437808
20.

Hormones and radiation therapy in locally advanced adenocarcinoma of the prostate.

Lawton CA.

Semin Radiat Oncol. 2003 Apr;13(2):141-51. Review.

PMID:
12728443

Supplemental Content

Support Center